While Amgen Sees Success For Two Growth Drivers, Headwinds Remain

Breakthrough Drugs Sotorasib, Tezepelumab Edge Closer To Market

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.

Amgen sign at biopharmaceutical company campus in Silicon Valley, biotech company headquartered in Thousand Oaks - South San Francisco, CA, USA - 2020
Amgen's sotorasib is filed with the US FDA; tezepelumab is being prepared for filings • Source: Shutterstock

Amgen, Inc. entered 2021 with two new high-profile potential additions to its commercial portfolio – sotorasib for non-small cell lung cancer patients with KRAS G12C mutations and tezepelumab for severe asthma. But while Amgen executive vice presidents David Reese and Murdo Gordon are looking forward to bringing these therapies to market in the next year or so, COVID-19 impacts on sales and competitive pressures remain near-term headwinds to the company’s growth.

Scrip spoke with Reese, EVP of research and development, and Gordon, EVP of global commercial operations, about pivotal data, filing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains